Descripción del proyecto
Gestión de la diabetes: hacia los datos de la vida real
Los ensayos clínicos se consideran el patrón de referencia para investigar la seguridad y eficacia de fármacos o intervenciones terapéuticas. Sin embargo, los datos de la vida real, que se recopilan de forma habitual a partir de diversas fuentes como dispositivos, dispositivos ponibles e historiales médicos electrónicos, están ganando terreno. El objetivo del proyecto REDDIE, financiado con fondos europeos, es respaldar el uso de los datos de la vida real para el tratamiento de la diabetes «mellitus», un trastorno crónico que afecta a millones de personas en todo el mundo. El consorcio utilizará datos de registros nacionales para evaluar los resultados de intervenciones específicas. Además, establecerá normas para aceptar y aplicar los datos de la vida real en el proceso de evaluación de medicamentos y otras intervenciones para la prevención y el tratamiento de la diabetes.
Objetivo
Randomised controlled trials are the cornerstone of evidence-based medicine. However, the digitisation of real-world data (RWD) including data from devices, wearables, and electronic health records in large national registries provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health. These data are particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together. To better utilise RWD in diabetes for regulatory decision making, a development of standards, guidance, and an assessment of the efficacy to effectiveness gap is needed.
REDDIE (Real-World Evidence for Decisions in Diabetes) aims to explore how RWD can complement RCTs to improve efficacy, safety, and value for money of technologies to prevent and treat diabetes. The overall aim of REDDIE is to support the use of RWD in diabetes and health-related research, which will maximise Europe’s scientific expertise and know-how to benefit people with diabetes, resulting in safer, more efficient, and cost-effective interventions.
We thus aim to engage with stakeholders such as regulatory and HTA authorities and co-develop evidentiary standards for the collection, assessment, and acceptability of RWD. We will then develop and validate state-of-the art modelling techniques using synthetic data derived from large national registries to better assess outcomes of interventions using RWD. We will use data from four large national registries to elucidate the gap between outcomes in RCTs and RWD studies, and understand the factors that affect this gap. Finally, we will test the ability of machine learning to facilitate the better use of RWD.
REDDIE will generate standards for RWD use for the evaluation of medicines and other interventions by regulatory authorities and HTA bodies.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
8010 Graz
Austria